Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants

Core Viewpoint - Oragenics, Inc. has announced a public offering of up to 800,000 shares of Series H Convertible Preferred Stock and Warrants, aiming to raise approximately $20 million to fund ongoing clinical trials and other corporate purposes [1][2]. Group 1: Offering Details - The offering includes 800,000 shares of Preferred Stock and Warrants to purchase an additional 800,000 shares at an exercise price of $25.00 per share [1]. - The combined public offering price for each share of Preferred Stock and accompanying Warrant is set at $25.00 [1]. - The Preferred Stock can be converted into common stock at a conversion price of $2.50 per share [1]. Group 2: Financial Proceeds and Use - Gross proceeds from the offering are expected to be approximately $20 million before deducting fees and expenses [2]. - The net proceeds will be used to fund ongoing ONP-2 concussion clinical trials, repay a $3 million bridge note, and for general corporate purposes [2]. Group 3: Placement Agent and Regulatory Compliance - Dawson James Securities, Inc. is acting as the sole placement agent for the offering [3]. - The offering is being conducted under a registration statement filed with the SEC, which became effective on June 30, 2025 [4].